---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-017259"
form_type: "8-K"
ticker: "CSBR"
cik: "0000771856"
company_name: "CHAMPIONS ONCOLOGY, INC."
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T14:29:21.477616+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Champions Oncology Q3: study service rev record $16.6M (+32%); net loss $279k vs prior yr profit $4.5M

## Summary
- Record study service revenue $16.6M, up 32% YoY; total revenue $16.6M vs $17.0M prior year.
- GAAP net loss of $279k (incl $423k stock comp, $341k D&A) vs net income $4.5M prior year.
- Adjusted EBITDA $574k, down from $5.1M prior year; cost margins compressed by outsourced radiolabeling.
- Ended quarter with $7.1M cash, no debt; management reaffirms full-year positive adj. EBITDA and revenue growth.
- R&D expense $2.3M, up 32% for data platform and Corellia investments.

## SEC filing metadata
- accession: 0001628280-26-017259
- form_type: 8-K
- ticker: CSBR
- cik: 0000771856
- company_name: CHAMPIONS ONCOLOGY, INC.
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/771856/000162828026017259/0001628280-26-017259-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/771856/000162828026017259/csbr-20260312.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-017259
- JSON: https://secwatch.observer/filing/0001628280-26-017259.json
- Plain text: https://secwatch.observer/filing/0001628280-26-017259.txt

## Key facts
- Earnings Releases
  CHAMPIONS ONCOLOGY, INC. reported third quarter of fiscal 2026, ended January 31, 2026 results: revenue $16.6 million, net income $279,000. Guidance reaffirmed.
  - Period: third quarter of fiscal 2026, ended January 31, 2026
  - Revenue: $16.6 million
  - Net income: $279,000
  - Guidance: reaffirmed
  - Result: reported results
  source text: reference in such a filing. --- EX-99.1 (EX-99.1) --- NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104 Champions Oncology Reports Revenue of $16.6 Million Company remains on track to deliver year-over-year revenue growth and positive adjusted EBITDA for the fiscal year Hackensack, NJ – March 12 , 2026 – Champions Oncology, Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/771856/000162828026017259/0001628280-26-017259-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.